OA10813A - New 19-nor-pregnene derivatives - Google Patents

New 19-nor-pregnene derivatives Download PDF

Info

Publication number
OA10813A
OA10813A OA9800117A OA9800117A OA10813A OA 10813 A OA10813 A OA 10813A OA 9800117 A OA9800117 A OA 9800117A OA 9800117 A OA9800117 A OA 9800117A OA 10813 A OA10813 A OA 10813A
Authority
OA
OAPI
Prior art keywords
compound
alkyl
formula
hydrogen
compounds
Prior art date
Application number
OA9800117A
Other languages
English (en)
Inventor
Alain Piasco
Jean Lafay
Remi Delansorne
Jacques Paris
Jean-Claude Pascal
Original Assignee
Theramex
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Theramex filed Critical Theramex
Publication of OA10813A publication Critical patent/OA10813A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/0005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
    • C07J7/001—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group
    • C07J7/004—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group substituted in position 17 alfa
    • C07J7/0045—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group substituted in position 17 alfa not substituted in position 16
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/34—Gestagens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J21/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having an oxygen-containing hetero ring spiro-condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J21/005—Ketals
    • C07J21/006—Ketals at position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring the nitrogen atom being directly linked to the cyclopenta(a)hydro phenanthrene skeleton
    • C07J41/0016—Oximes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J53/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by condensation with a carbocyclic rings or by formation of an additional ring by means of a direct link between two ring carbon atoms, including carboxyclic rings fused to the cyclopenta(a)hydrophenanthrene skeleton are included in this class
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J53/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by condensation with a carbocyclic rings or by formation of an additional ring by means of a direct link between two ring carbon atoms, including carboxyclic rings fused to the cyclopenta(a)hydrophenanthrene skeleton are included in this class
    • C07J53/002—Carbocyclic rings fused
    • C07J53/004—3 membered carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C07J71/0005—Oxygen-containing hetero ring
    • C07J71/001—Oxiranes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Epidemiology (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
OA9800117A 1996-01-22 1998-07-22 New 19-nor-pregnene derivatives OA10813A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP96400146A EP0785212A1 (en) 1996-01-22 1996-01-22 New 19-nor-pregnene derivatives

Publications (1)

Publication Number Publication Date
OA10813A true OA10813A (en) 2003-01-28

Family

ID=8225217

Family Applications (1)

Application Number Title Priority Date Filing Date
OA9800117A OA10813A (en) 1996-01-22 1998-07-22 New 19-nor-pregnene derivatives

Country Status (36)

Country Link
US (1) US6180803B1 (ko)
EP (2) EP0785212A1 (ko)
JP (2) JP4368945B2 (ko)
KR (1) KR100396902B1 (ko)
CN (1) CN1187366C (ko)
AP (1) AP1176A (ko)
AR (1) AR005500A1 (ko)
AT (1) ATE184015T1 (ko)
BR (1) BR9707064A (ko)
CA (1) CA2243504C (ko)
CO (1) CO4810230A1 (ko)
CZ (1) CZ292047B6 (ko)
DE (1) DE69700470T2 (ko)
DZ (1) DZ2169A1 (ko)
EE (1) EE03692B1 (ko)
ES (1) ES2140961T3 (ko)
GR (1) GR3031954T3 (ko)
HK (1) HK1018216A1 (ko)
HU (1) HU221796B1 (ko)
ID (1) ID15840A (ko)
IL (1) IL125379A (ko)
IS (1) IS1902B (ko)
JO (1) JO1971B1 (ko)
MY (1) MY116845A (ko)
NO (1) NO309572B1 (ko)
NZ (1) NZ330954A (ko)
OA (1) OA10813A (ko)
PE (1) PE55998A1 (ko)
PL (1) PL185608B1 (ko)
RU (1) RU2166509C2 (ko)
SI (1) SI0886645T1 (ko)
TN (1) TNSN97015A1 (ko)
TR (1) TR199801399T2 (ko)
TW (1) TW411345B (ko)
WO (1) WO1997027210A1 (ko)
ZA (1) ZA97521B (ko)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2776191B1 (fr) * 1998-03-23 2002-05-31 Theramex Composition hormonale topique a effet systemique
AR028110A1 (es) * 2000-06-02 2003-04-23 Astrazeneca Ab Nuevo proceso
US20070225379A1 (en) * 2001-08-03 2007-09-27 Carrara Dario Norberto R Transdermal delivery of systemically active central nervous system drugs
US7198801B2 (en) * 2000-08-03 2007-04-03 Antares Pharma Ipl Ag Formulations for transdermal or transmucosal application
AU8206401A (en) 2000-08-03 2002-02-18 Antares Pharma Ipl Ag Novel composition for transdermal and/or transmucosal administration of active compounds that ensures adequate therapeutic levels
US8980290B2 (en) 2000-08-03 2015-03-17 Antares Pharma Ipl Ag Transdermal compositions for anticholinergic agents
US20040198706A1 (en) * 2003-03-11 2004-10-07 Carrara Dario Norberto R. Methods and formulations for transdermal or transmucosal application of active agents
FR2814074B1 (fr) * 2000-09-15 2003-03-07 Theramex Nouvelles compositions estro-progestatives topiques a effet systemique
ES2535430T3 (es) * 2003-09-03 2015-05-11 Miscon Trading S.A. Métodos para el tratamiento de la endometriosis
PL1670433T3 (pl) 2003-10-10 2013-03-29 Ferring Bv Przezskórna formulacja farmaceutyczna do zmniejszania pozostałości na skórze
US7425340B2 (en) * 2004-05-07 2008-09-16 Antares Pharma Ipl Ag Permeation enhancing compositions for anticholinergic agents
WO2006125642A1 (en) * 2005-05-27 2006-11-30 Antares Pharma Ipl Ag Methods and apparatus for transdermal or transmucosal application of testosterone
CA2646667C (en) 2006-04-21 2014-03-11 Antares Pharma Ipl Ag Methods of treating hot flashes with formulations for transdermal or transmucosal application
WO2008067991A2 (en) * 2006-12-08 2008-06-12 Antares Pharma Ipl Ag Skin-friendly drug complexes for transdermal administration
PT2782584T (pt) 2011-11-23 2021-09-02 Therapeuticsmd Inc Preparações e terapias de substituição para hormonoterapias naturais combinadas
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
JP2017516768A (ja) 2014-05-22 2017-06-22 セラピューティックスエムディー インコーポレーテッドＴｈｅｒａｐｅｕｔｉｃｓｍｄ， Ｉｎｃ． 天然の併用ホルモン補充療法剤及び療法
US9173915B1 (en) * 2014-10-10 2015-11-03 Peter F. Kador Antioxidant eye drops
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
CN109364019B (zh) * 2015-09-02 2021-12-28 盛世泰科生物医药技术(苏州)有限公司 一种用于预防和治疗白内障的眼用制剂及其制备方法
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
KR20180126582A (ko) 2016-04-01 2018-11-27 쎄러퓨틱스엠디, 인코퍼레이티드 스테로이드 호르몬 약제학적 조성물
CN110452279B (zh) * 2019-05-13 2022-04-08 株洲千金药业股份有限公司 三萜类化合物和其药学上可接受的盐及制备方法和应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1593524A1 (de) * 1951-01-28 1970-08-13 Schering Ag Verfahren zur Herstellung von 1,2alpha-Methylen-19-nor-steroiden
DE1087127B (de) * 1958-12-13 1960-08-18 Schering Ag Verfahren zur Herstellung neuer progestativ wirksamer Ester von 2-Methyl-Steroiden
FR1405214A (fr) * 1962-06-21 1965-07-09 Rhone Poulenc Sa Nouveaux stéroïdes de la série du prégnane et leur procédé de préparation
FR1525916A (fr) * 1965-11-09 1968-05-24 Schering Ag Stéroïdes portant un groupe méthylène en position 1.2 et leur préparation
US3835160A (en) * 1967-06-06 1974-09-10 Schering Corp 3{40 -keto-2{40 ,3{40 -seco-1{40 -(2{40 )-yne steroidal derivatives, methods for their manufacture, and compounds produced thereby
US3891677A (en) * 1967-06-06 1975-06-24 Schering Corp 17{60 ,20,20,21-Bismethylenedioxy-4,5-seco-3-pregnyne-5-ones
BE757286A (fr) * 1969-10-10 1971-04-09 Ciba Geigy Nouvelle 6alpha-methyl-19-nor progesterone et procede pour sa preparation
CH538462A (de) * 1970-10-07 1973-06-30 Ciba Geigy Ag Ein neues Verfahren zur Herstellung von 6a-Methyl-19-nor-pregnenen
DE3402330A1 (de) * 1984-01-20 1985-07-25 Schering AG, 1000 Berlin und 4709 Bergkamen 1(alpha),2(alpha)-methylen-6-methylen- und 6(alpha)-methyl-pregnene, verfahren zu deren herstellung und diese enthaltende pharmazeutische praeparate

Also Published As

Publication number Publication date
CN1209811A (zh) 1999-03-03
IL125379A0 (en) 1999-03-12
ZA97521B (en) 1997-08-04
MY116845A (en) 2004-04-30
JO1971B1 (en) 1997-12-15
TNSN97015A1 (fr) 2005-03-15
CZ230798A3 (cs) 1998-11-11
AU1595597A (en) 1997-08-20
RU2166509C2 (ru) 2001-05-10
HUP9900684A3 (en) 1999-11-29
TR199801399T2 (xx) 1998-10-21
WO1997027210A1 (en) 1997-07-31
DE69700470T2 (de) 2000-03-30
NZ330954A (en) 1998-10-28
BR9707064A (pt) 1999-12-28
HK1018216A1 (en) 1999-12-17
SI0886645T1 (en) 1999-12-31
GR3031954T3 (en) 2000-03-31
PL185608B1 (pl) 2003-06-30
AP9801299A0 (en) 1998-09-30
EP0886645A1 (en) 1998-12-30
CA2243504A1 (en) 1997-07-31
NO309572B1 (no) 2001-02-19
AR005500A1 (es) 1999-06-23
PE55998A1 (es) 1998-10-01
CA2243504C (en) 2004-03-30
DZ2169A1 (fr) 2002-12-25
EP0886645B1 (en) 1999-09-01
NO983356D0 (no) 1998-07-21
AP1176A (en) 2003-06-30
HUP9900684A2 (hu) 1999-07-28
EE9800219A (xx) 1998-12-15
IS4800A (is) 1998-07-21
IL125379A (en) 2003-05-29
ID15840A (id) 1997-08-14
JP2000503980A (ja) 2000-04-04
ES2140961T3 (es) 2000-03-01
DE69700470D1 (de) 1999-10-07
EE03692B1 (et) 2002-04-15
EP0785212A1 (en) 1997-07-23
NO983356L (no) 1998-07-21
ATE184015T1 (de) 1999-09-15
PL327998A1 (en) 1999-01-04
HU221796B1 (hu) 2003-01-28
TW411345B (en) 2000-11-11
CN1187366C (zh) 2005-02-02
JP4368945B2 (ja) 2009-11-18
KR19990081895A (ko) 1999-11-15
IS1902B (is) 2003-11-20
CZ292047B6 (cs) 2003-07-16
JP2009167188A (ja) 2009-07-30
KR100396902B1 (ko) 2004-05-03
US6180803B1 (en) 2001-01-30
AU708135B2 (en) 1999-07-29
CO4810230A1 (es) 1999-06-30

Similar Documents

Publication Publication Date Title
EP0886645B1 (en) New 19-nor-pregnene derivatives
EP0785211A1 (en) New substituted 19-nor-pregnane derivatives
AU4401100A (en) Ent-steroids as selectively active estrogens
RU2159774C2 (ru) Производные сульфамата, способ их получения и фармацевтические составы
US4859370A (en) 9 alpha, 11 beta-substituted and 11 beta-substituted estranes
JPS6220998B2 (ko)
EP0145493A2 (en) 11-Difluoromethyl and 11-fluoromethylene steroids
JP3993228B2 (ja) １、３、５▲（１０）▼−エストラトリエンの経口活性誘導体
US7199115B2 (en) 17α-fluorosteroids, pharmaceutical compositions containing 17α-fluorosteroids and a method of making them
JPH0515720B2 (ko)
ES2393942T3 (es) 16,ALFA-FLUORO-ESTRATIENOS 8-BETA- sustituidos en calidad de estrógenos selectivamente activos
AU708135C (en) New 19-nor-pregnene derivatives
HU197925B (en) Process for producing 11 beta-(aminophenyl)-steroids and pharmaceutical compositions comprising same
US4567000A (en) 11-Difluoromethylene steroids
AU2002210470B2 (en) 4-halogenated 17-methylene steroids, method for the production thereof and pharmaceutical compositions containing these compounds
US3661940A (en) Derivatives of 21-methyl-19-norpregnanes
US4557867A (en) 11β-Difluoromethyl and (E)- and (Z)-11-fluoromethylene steriods
JP2007532688A (ja) １７α−フルオロ−１７β−ヒドロキシイミノメチルステロイド、それらを製造する方法および前記化合物を含んでなる医薬組成物
US3719670A (en) Substituted carbinol derivatives
US3501510A (en) Estriol derivatives